Immatics N.V. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
IMTX Nasdaq 2836 www.immatics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Immatics N.V.

Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma - May 31st, 2025 6:00 am
We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely - May 15th, 2025 4:40 am
Immatics Announces First Quarter 2025 Financial Results and Business Update - May 13th, 2025 5:00 am
Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting - Apr 23rd, 2025 8:00 am
Immatics Full Year 2024 Earnings: Beats Expectations - Mar 28th, 2025 4:56 am
Immatics Announces Full Year 2024 Financial Results and Business Update - Mar 27th, 2025 5:00 am
Investors in Immatics (NASDAQ:IMTX) have unfortunately lost 53% over the last year - Feb 9th, 2025 5:29 am
Immatics N.V. (NASDAQ:IMTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Nov 20th, 2024 4:59 am
Immatics Sees Revenue Surge Despite R&D Expenses - Nov 19th, 2024 5:25 am
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME - Nov 18th, 2024 5:00 am
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME - Nov 8th, 2024 3:00 pm
Immatics N.V. (NASDAQ:IMTX) is a favorite amongst institutional investors who own 50% - Oct 23rd, 2024 5:11 am
Immatics Advances IMA203 to Phase 3 Trial in Melanoma - Oct 11th, 2024 4:57 am
Immatics Announces Pricing of $150 Million Public Offering - Oct 10th, 2024 6:50 pm
Immatics Announces Proposed $150 Million Public Offering - Oct 10th, 2024 5:30 am
Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial - Oct 10th, 2024 4:30 am
Immatics N.V. (IMTX) Receives Buy Rating from Analysts - Oct 9th, 2024 6:03 am
Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024 - Oct 4th, 2024 7:00 am
Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update - Sep 16th, 2024 3:25 am
Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024 - Sep 6th, 2024 5:00 am